Vertex Software faces strong competition and slower growth, leading to a neutral rating. See why VERX stock remains pricey ...

We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take ...

Vertex Pharmaceuticals Inc. closed 5.23% below its 52-week high of $519.88, which the company achieved on November 8th.

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

The equity portion of the Abrdn Healthcare Investors Fund fell (gross of fees) but outperformed its custom benchmark over the ...

Shares of Vertex, Inc. (NASDAQ:VERX – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from ...

We feel now is a pretty good time to analyse Vertex, Inc.'s ( NASDAQ:VERX ) business as it appears the company may ...

Learn more about whether Elastic N.V. or Vertex, Inc. is a better investment based on AAII's A+ Investor grades, which ...

In a regulatory filing, Vertex Pharmaceuticals (VRTX) chief scientific officer David Altshuler disclosed the sale of 3,231 common shares of the ...

Learn more about whether Open Text Corporation or Vertex, Inc. is a better investment based on AAII's A+ Investor grades, ...

Vertex Pharmaceuticals will not advance clinical trials of a treatment for Type 1 diabetes after efficacy data failed to support further clinical advancement.

Vertex is expected to post earnings of $4.19 per share for the current quarter, representing a year-over-year change of -12%. Over the last 30 days, the Zacks Consensus Estimate has changed +0.4%.